Q4 2024 · 13F-HR
Atle Fund Management ABholdings as filed
Filed 2025-02-04 · accession 0001381843-25-000002
$210.8M
Reported value
36
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 532457108 | LLY | ELI LILLY & CO | $28.7M | 13.6% | 37,068 | Common | SOLE |
| 91324P102 | UNH | UNITEDHEALTH GROUP INC | $17.9M | 8.48% | 35,202 | Common | SOLE |
| 00287Y109 | ABBV | ABBVIE INC | $16.0M | 7.58% | 90,723 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $13.8M | 6.56% | 154,222 | Common | SOLE |
| 883556102 | TMO | THERMO FISHER SCIENTIFIC INC | $12.9M | 6.13% | 24,896 | Common | SOLE |
| 58933Y105 | MRK | MERCK & CO INC | $10.4M | 4.93% | 105,727 | Common | SOLE |
| 863667101 | SYK | STRYKER CORPORATION | $9.3M | 4.41% | 25,660 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $9.3M | 4.40% | 67,763 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $7.7M | 3.64% | 266,499 | Common | SOLE |
| 92532F100 | VRTX | VERTEX PHARMACEUTICALS INC | $7.6M | 3.60% | 22,257 | Common | SOLE |
| 03073E105 | COR | CENCORA INC | $7.3M | 3.47% | 32,553 | Common | SOLE |
| 031162100 | AMGN | AMGEN INC | $7.1M | 3.37% | 27,414 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $5.9M | 2.82% | 71,138 | Common | SOLE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $5.1M | 2.40% | 68,296 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $4.8M | 2.28% | 116,692 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $4.7M | 2.22% | 60,057 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $4.1M | 1.95% | 120,501 | Common | SOLE |
| 14149Y108 | CAH | CARDINAL HEALTH INC | $3.6M | 1.72% | 30,680 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $3.6M | 1.69% | 138,983 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $3.3M | 1.56% | 42,071 | Common | SOLE |
| 902673102 | UFPT | UFP TECHNOLOGIES INC | $3.2M | 1.50% | 23,159 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $3.1M | 1.46% | 326,840 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $2.8M | 1.34% | 103,032 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $2.7M | 1.27% | 62,161 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $2.6M | 1.24% | 62,521 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $2.1M | 0.99% | 39,573 | Common | SOLE |
| 07725L102 | ONC | BEIGENE LTD | $2.0M | 0.95% | 10,900 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $1.5M | 0.70% | 9,202 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $1.4M | 0.65% | 390,000 | Common | SOLE |
| 86627T108 | SMMT | SUMMIT THERAPEUTICS INC | $1.3M | 0.62% | 101,177 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $1.2M | 0.56% | 98,304 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $1.1M | 0.50% | 479,644 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $984,822 | 0.47% | 30,940 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $764,842 | 0.36% | 538,621 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $652,919 | 0.31% | 34,328 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $554,297 | 0.26% | 247,454 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.